Fonar settles patent dispute with Elscint
MRI developer Fonar has announced that it has resolved its pending patent infringement litigation with Elscint. Terms of the agreement were not released.The deal adds another to the list of companies that have settled MRI patent disputes with Fonar.
MRI developer Fonar has announced that it has resolved its pending patent infringement litigation with Elscint. Terms of the agreement were not released.
The deal adds another to the list of companies that have settled MRI patent disputes with Fonar. Hitachi, Philips, Siemens, Toshiba, and Shimadzu have all reached settlements with them in recent years, while GE lost its legal battle with the firm in 1997, paying a total of $128.7 million (SCAN 7/9/97).
In other Fonar news, the Melville, NY-based company has appointed Sol Ginzburg as vice president of sales. He had recently served as director of international sales for the firm.
Fonar also announced that Pennsylvania Medical Group has acquired another of its Quad 12000 devices for an imaging center in Reading, PA. The group already employs a Quad 12000 scanner at an imaging facility in Philadelphia. Fonar valued the groups latest purchase at $1.2 million.
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.
Could an Emerging PET Tracer be a Game Changer for Detecting Hepatocellular Carcinoma?
June 23rd 2025In addition to over 90 percent sensitivity in detecting hepatocellular carcinoma (HCC), the glypican-3 (GPC3) targeted PET tracer 68Ga-aGPC3-scFv appeared to be advantageous in identifying HCC tumors smaller than one centimeter, according to pilot study findings presented at the SNMMI conference.
SNMMI: What a New Meta-Analysis Reveals About Radiotracers for PET/CT Detection of PCa
June 22nd 2025While (68Ga)Ga-PSMA-11 offers a pooled sensitivity rate of 92 percent for prostate cancer, (18F)-based radiotracers may offer enhanced lesion detection as well as improved imaging flexibility, according to a meta-analysis presented at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.
